Background Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic
kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior …

The use of direct oral anticoagulants for stroke prevention in patients with non-valvular atrial
fibrillation (NVAF) is robust. However, the efficacy and safety of different dosage in patients …

Background and Objectives: Real-world evidence of apixaban treatment in patients with
chronic kidney disease remains scarce. This study aimed to compare the relative risk of …

Background Real-world information regarding the use of direct oral anticoagulants therapy
and the outcome in patients with renal dysfunction is limited. Objectives To evaluate the …

Importance Renal impairment confers an increased risk of stroke, bleeding, and death in
patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in …

Aims Atrial fibrillation (AF) is common among patients with impaired renal function.
Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with …

BACKGROUND Randomized controlled trials (RCTs) of direct oral anticoagulants (DOACs)
included a low proportion of atrial fibrillation (AF) patients with chronic kidney disease …

Background: Compared with the general population, patients with advanced chronic kidney
disease have a> 10-fold higher burden of atrial fibrillation. Limited data are available …

Rationale & Objective Head-to-head data comparing the effectiveness and safety of oral
anticoagulants in patients with atrial fibrillation (AF) and advanced chronic kidney disease …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …